

#53532

Date:	November 09, 2023
Subject:	EQRx, Inc Contract Adjustment Option Symbol: 11/09/2023 - EQRX remains EQRX 11/10/2023 - EQRX becomes RVMD1 Date: 11/09/2023
Contract Adjustment	
Date:	November 09, 2023
Option Symbol:	11/09/2023 - EQRX remains EQRX (with adjusted deliverable described below) 11/10/2023 - EQRX changes to RVMD1
Strike Divisor:	1
Contracts Multiplier:	1
New Multiplier:	100 (e.g., a premium of 1.50 yields \$150; a strike of 2.50 yields \$250.00)
New Deliverable Per Contract:	 1) 100 x a number of Revolution Medicines, Inc. (RVMD) Common Shares based on the exchange ratio calculated as described in the EQRX/RVMD Proxy Statement/Prospectus dated September 29, 2023 ("Proxy") 2) Cash in lieu of fractional RVMD shares, if any Note: Once determined the cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price changes of any
	security.
CUSIP:	RVMD: 76155X100

Delayed Settlement

OCC will delay settlement of the RVMD component and the cash portion of the RVMD1 deliverable until the final merger consideration and cash in lieu of fractional RVMD shares amount, if any, are determined. Upon determination of the final merger consideration and the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate number of RVMD shares and appropriate cash amount if any.

Background

On November 8, 2023, Shareholders of EQRx, Inc. (EQRX) voted concerning the proposed merger with Revolution Medicines, Inc. (RVMD). The merger was approved and subsequently consummated before the open on November 9, 2023. As a result, each existing EQRX Common Share will be converted into the right to receive a number of RVMD shares based on the exchange ratio calculated as described in the Proxy. Cash will be paid in lieu of fractional RVMD shares.

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.